Abstract
A recent clinical trial provided evidence that pre-exposure prophylaxis (PrEP) has the potential to prevent HIV infection among people who inject drugs (PWID). We examined willingness to use PrEP among HIV-negative PWID in Vancouver, Canada (n = 543) to inform PrEP implementation efforts. One third (35.4 %) expressed willingness to use PrEP, with adjusted models indicating that younger age, no regular employment, requiring help injecting, engaging in sex work, and reporting multiple recent sexual partners were positively associated with willingness to use PrEP. Although willingness to use PrEP was low, PrEP was acceptable to some PWID at heightened risk for HIV infection.
Resumen
Reciente se demostró que la profilaxis pre-exposición (PrEP) puede evitar la infección por VIH entre personas que se inyectan drogas por vía intravenosa (PWID). Examinamos la predisposición a utilizar PrEP entre PWID HIV negativos en Vancouver, Canadá. La tercera parte (35.4 %) estaban dispuestos a usar PrEP. En el análisis ajustado menor edad, falta de empleo estable, requerir ayuda para inyectarse, trabajado sexual y haber tenido múltiples parejas sexuales recientemente se asociaron de manera positiva a utilizar PrEP. Aunque la predisposición global a utilizar PrEP fue baja, fue aceptable para algunas PWID a mayor riesgo para la infección por el VIH.
References
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in bangkok, thailand (the bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLOS ONE. 2014;9(1):E86584.
Baral SD, Stromdahl S, Beyrer C. The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Curr Opin HIV AIDS. 2012;7(6):563–8.
Campbell JD, Herbst JH, Koppenhaver RT, Smith DK. Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med. 2013;44(1 Suppl 2):S63–9.
Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S84–7.
Dutta MJ. Disseminating HIV pre-exposure prophylaxis information in underserved communities. Am J Prev Med. 2013;44(1 Suppl 2):S133–6.
Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BD. HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc. 2014;17:18899.
Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLOS One. 2012;7(1):E28238.
Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014.
Buxton J. Vancouver Site Report for the Canadian Community Epidemiology Network on Drug Use (CCENDU). 2003.
Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449–53.
Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.
Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
Urban Health Research Initiative. Drug situation in Vancouver; 2009. http://www.cfenet.ubc.ca/publications/drug-situation-vancouver-uhri-report. Accessed 5 Jan 2014.
U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Centers for disease control and prevention, 2014.
Aich TK, Dhungana M, Khanal R. Pattern of buprenorphine abuse among opioid abusers in Nepal. Indian J Psychiatry. 2010;52(3):250–3.
Gu J, Bai Y, Lau JT, Hao Y, Cheng Y, Zhou R, et al. Social environmental factors and condom use among female injection drug users who are sex workers in China. AIDS Behav. 2013.
Khan AA, Khan A. Performance and coverage of HIV interventions for injection drug users: insights from triangulation of programme, field and surveillance data from Pakistan. Int J Drug Policy. 2011;22(3):219–25.
Hayashi K, Suwannawong P, Ti L, Kaplan K, Wood E, Kerr T. High rates of midazolam injection and associated harms in Bangkok, Thailand. Addiction. 2013;108(5):944–52.
Kerr T, Marshall BD, Milloy MJ, Zhang R, Guillemi S, Montaner JS, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend. 2012;124(1–2):108–12.
Fairbairn N, Small W, Van Borek N, Wood E, Kerr T. Social structural factors that shape assisted injecting practices among injection drug users in Vancouver, Canada: a qualitative study. Harm Reduct J. 2010;7:20.
Richardson LA, Milloy MJ, Kerr TH, Parashar S, Montaner JS, Wood E. Employment predicts decreased mortality among HIV-seropositive illicit drug users in a setting of universal HIV care. J Epidemiol Community Health. 2014;68(1):93–6.
Goldenberg SM, Chettiar J, Simo A, Silverman JG, Strathdee SA, Montaner JS, et al. Early sex work initiation independently elevates odds of HIV infection and police arrest among adult sex workers in a Canadian setting. J Acquir Immune Defic Syndr. 2014;65(1):122–8.
Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, Steward WT, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (prep) in clinical settings to prevent HIV infection. PLOS One. 2012;7(7):E40603.
Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD, Study A. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort 1988–2000: description and determinants. Am J Epidemiol. 2003;158(7):695–704.
Acknowledgments
The study was supported by the US National Institutes of Health (R01DA011591). Thomas Kerr is supported by the Michael Smith Foundation for Health Research and the Canadian Institutes of Health Research. Mark Lurie received partial support from the NIH through two research Grants (1R01MH083539-01 and 1R24HD077976-01). Daniel Escudero is supported by an NIH Grant (F31-DA037808). We would also like to thank Dr. Kenneth Mayer for his assistance with developing the survey instrument.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Escudero, D.J., Kerr, T., Wood, E. et al. Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting. AIDS Behav 19, 752–757 (2015). https://doi.org/10.1007/s10461-014-0867-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-014-0867-z